Achieve Life Sciences, Inc.
ACHV- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000949858
In the last 90 days, Achieve Life Sciences, Inc. insiders filed 0 open-market purchases and 1 sale; 111 institutions reported holding it in 13F filings for Q2 2026, worth $538.7M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Achieve Life Sciences, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 66 | 66 | 0 |
| Shares | 26.2M | 15.5M | −10.7M (−40.8%) |
| Value | $59.3M | $48.9M | −$10.4M (−17.5%) |
New holders (22)
Institutions that held Achieve Life Sciences, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (22)
Institutions that held Achieve Life Sciences, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Hudson Bay Capital Management LP | 1,173,532 | $2.65M |
| Heights Capital Management, Inc | 989,509 | $2.24M |
| Stonepine Capital Management, LLC | 333,333 | $753.3K |
| Long Focus Capital Management, LLC | 248,099 | $560.7K |
| Highbridge Capital Management LLC | 132,937 | $300.4K |
| Y-Intercept (Hong Kong) Ltd | 116,409 | $263.1K |
| Alpine Global Management, LLC | 100,000 | $226.0K |
| Jane Street Group, LLC | 70,452 | $159.2K |
| Brevan Howard Capital Management LP | 64,348 | $145.4K |
| Aster Capital Management (DIFC) Ltd | 60,514 | $136.8K |
| Jain Global LLC | 38,806 | $87.7K |
| AQR Capital Management LLC | 25,300 | $57.2K |
| Citadel Advisors LLC | 24,718 | $55.9K |
| DRW Securities, LLC | 12,599 | $28.5K |
| Simplex Trading, LLC | 5,152 | $11.0K |
| Tower Research Capital LLC (TRC) | 4,586 | $10.4K |
| Clearstead Advisors, LLC | 221 | $500 |
| Skopos Labs, Inc. | 210 | $475 |
| Nisa Investment Advisors, LLC | 52 | $118 |
| Essential Partners LLC | 29 | $66 |
| IFP Advisors, Inc | 0 | $25 |
| True Wealth Design, LLC | 11 | $25 |